Cancer genetic or not, Special Report: Fast machines, genes and the future of medicine
Subscribe What is EndoPredict? EndoPredict is a 2nd generation multi-gene breast cancer recurrence test cancer genetic or not pre- or postmenopausal women newly diagnosed with early-stage breast cancer. Created for cancer genetic or not purpose of highly accurate assessment of 5 to year risk of distant recurrence of the disease EndoPredict combines into an unique indicator EPClin score gene expression with clinically pathological features providing outstanding prognostic performance that will ensure the healthcare professional that chemotherapy is or is not required to accompany endocrine treatment.
Considering these aspects, realizing that the cancer has a high or low risk of recurrence can help patients and doctors cancer genetic or not if chemotherapy after surgery is or is not necessary to accompany endocrine therapy. What DNA sample is required to perform the test?
EndoPredict requires a simple tumor tissue sample that is customarily prepared for the pathology exam upon surgical tumor removal. The latest diagnostic and prognostic technology allows healthcare specialists to determine suitable cancer genetic or not procedures based completely on the needs and DNA of the patient. Therefore, the decision of breast cancer therapy increasingly depends on your own mix of gene markers.
Cancer will no longer be 'a death sentence': DNA-based treatment to transform lives within 10 years
In this context, EndoPredict reveals critical information about the way that a tumor is likely to react at a genetic level. Why is EndoPredict relevant?
For example, patients with advanced breast cancer are tested to determine if their tumours have a particular type of the HER2 gene, responsible for 20 per cent of cases. Skin cancer patients with a particular type of melanoma may also be prescribed the life-prolonging drug Vemurafenib.
At the same time it can convince those at low risk of recurrence that chemotherapy is not mandatory. Thus, the test is practically an important step ahead cancer genetic or not the goal of truly customized care, helping breast cancer therapists cancer genetic or not avoid both over- and under treatment of breast cancer with chemotherapy.
When do breast cancer metastases occur? Breast cancer metastases mostly happen within the first three years following the initial diagnosis.
One of the objectives of EndoPredict test is to calculate the tendency for cancer recurrence or late metastases. Cancer genetic or not is the best treatment to lower the risk of developing a recurrence of the breast cancer?
- And he was surprised by what he learned.
For early and locally advanced breast cancer the first clinical step is, of course, to surgically remove the tumor. The next step requires a more complex decision. Around half of the intermediate patients currently receive unnecessary chemotherapy, which is very stressful for the organism, has serious side-effects, is toxic by nature and has a significant impact on mortality.
For that reason, it is very important to be able to identify the patients who would not adequately benefit from chemotherapy in any case and to be able to provide a more focused care, including systemic endocrine therapy, instead. EndoPredict manages to make this happen. The result?
- Special Report: Fast machines, genes and the future of medicine - Reuters
- EndoPredict – Nucleoshealthcare
- Prevenirea cancerului prin intermediul unor programe de screening
- The benefits are certain in some cases: life years gained for those with curable disease, avoidance of morbidity, reassurance that the disease is at a very early stage, avoiding expenses of treatment for advanced cancers and extra years of productivity.
The ones who would not adequately benefit from chemotherapy can be spared from this treatment and its correlated side-effects.
How does the test work?
Performed on preserved breast tumor tissue that was removed during the initial biopsy or surgery, the EndoPredict test analyzes the activity of rigorously selected prolipherative and hormone-receptor-related genes in breast cancer cells.
These genes are linked to the possibility that the cancer will come cancer genetic or not in a different part of the body within 15 years after initial diagnosis. The test includes the size of the breast tumor and whether or not the cancer is in the lymph nodes when calculating the risk score.
The scores are recognized either low-risk or high-risk: an EPclin Risk Score higher than 3. With the help of our partner physicians, experts in genetic counseling in breast cancer, you will find out the benefits of the EndoPredict test, understand the clinical results and make the right decisions for your future health.
TR Hereditary Cancer Syndromes: "The Angelina Effect" Angelina Jolie's announcement triggered an increase in the number of people in high risk being screened and this is a very important step so they can minimize the chances of the disease developing.
Fill this form to get in touch with a doctor for a clinic consultation and testing.